Jan 27, 2020 - Is (LLY) Outperforming Other Medical Stocks This Year?
Jan 24, 2020 - Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
Jan 22, 2020 - Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
Jan 17, 2020 - The Midwest's largest drugmaker isn't finished making mid-sized deals.
Jan 17, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Jan 17, 2020 - Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Jan 16, 2020 - J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
Jan 16, 2020 - The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Jan 14, 2020 - Eli Lilly and Company (NYSE:LLY) 38th Annual JPMorgan Healthcare Conference Call January 14, 2020 5:30 PM ET Company Participants Dave Ricks – Chairman and Chief Executive Officer Conference Call Part
Jan 13, 2020 - Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.